Results 191 to 200 of about 12,025 (204)

Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients

Respiratory Medicine, 2011
Charles Fogarty
exaly  

Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects

Frontiers in Pharmacology, 2022
exaly  

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD

Therapeutic Advances in Respiratory Disease, 2019
Mousumi Biswas, Patrick Darken, Mario Ouwens   +2 more
exaly  

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

Advances in Therapy, 2020
Patrick Darken, Gary Ferguson, Barinder Singh   +2 more
exaly  

Aclidinium bromide, a novel long-acting muscarinic antagonist (LAMA)

2010
Amadeu Gavaldà, Esther Garcia-Gil
openaire   +1 more source

Clinical Efficacy of Long-Acting β2 Agonists and Long-Acting Muscarinic Antagonist for Moderate to Severe Chronic Obstructive Pulmonary Disease

Pharmaceutical Chemistry Journal, 2023
exaly  

Comparative Effectiveness of Long‐Acting Beta2‐Agonist Combined with a Long‐Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease

Pharmacotherapy, 2017
A Simon Pickard
exaly  

Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies

Pulmonary Pharmacology and Therapeutics, 2018
Dave Singh, Edmund Moran, Brett Haumann   +2 more
exaly  

Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs

Expert Opinion on Investigational Drugs, 2017
Chris Droege, Neil E Ernst, Ralph J Panos   +2 more
exaly  

Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile

Life Sciences, 2012
Amadeu Gavalda, Jesus Llenas, Jorge Beleta   +2 more
exaly